MYSTERIOUS: Evolus | Mind Blowing Facts

Needham Is Bullish On This Botox Equivalent Aesthetics Company

Needham initiated coverage on Evolus Inc (NASDAQ:EOLS) with a price target of $18.00 (43% upside) and a Buy rating. Evolus is a pure-play aesthetics company focused on growing the presence of Jeuveau, its new neurotoxin product, in the approximately $3 billion global wrinkle treatment market.  Jeuveau is a prescription medicine injected into muscles to improve…

Benzinga · Jun 24, 2022

Evolus's Return On Capital Employed Overview

According to data from Benzinga Pro, during Q1, Evolus's (NASDAQ:EOLS) reported sales totaled $33.91 million. Despite a 3.72% increase in earnings, the company posted a loss of $17.50 million.

Benzinga · Jun 10, 2022

Benzinga's Top Ratings Upgrades, Downgrades For May 13, 2022

Upgrades

Benzinga · May 13, 2022

Recap: Evolus Q4 Earnings

Evolus (NASDAQ:EOLS) reported its Q4 earnings results on Thursday, March 3, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Evolus missed estimated earnings by 73.68%, reporting an EPS of $-0.33 versus an estimate of $-0.19.

Benzinga · Mar 3, 2022

A Preview Of Evolus's Earnings

Evolus (NASDAQ:EOLS) is set to give its latest quarterly earnings report on Thursday, 2022-03-03. Here's what investors need to know before the announcement. Analysts estimate that Evolus will report an earnings per share (EPS) of $-0.19.

Benzinga · Mar 2, 2022

Evolus Expects Q4 FY21 Sales Better Than Anticipated, Issues FY22 Guidance

Evolus Inc (NASDAQ: EOLS) has posted 

Benzinga · Jan 26, 2022